Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13838139 | 0.84 | HPGD (0.89) | HPGDALDH1A1LMNAPRNPRECQL | |
| SCHEMBL8418260 | 0.83 | HPGD (0.57) | HPGDHDAC6HDAC4HDAC1HDAC3 | |
| SCHEMBL2223391 | 0.82 | ALDH1A1 (0.59) | HPGDHDAC6HDAC4HDAC1HDAC3 | |
| SCHEMBL8421789 | 0.82 | HPGD (0.56) | HPGDHDAC6HDAC4ALDH1A1LMNA | |
| SCHEMBL8421822 | 0.82 | HPGD (0.60) | HPGDHDAC6HDAC4ALDH1A1LMNA | |
| SCHEMBL8419847 | 0.81 | HPGD (0.55) | HPGDHDAC6HDAC4HDAC1HDAC3 | |
| SCHEMBL8421679 | 0.81 | HPGD (0.58) | HPGDHDAC6HDAC4ALDH1A1LMNA | |
| SCHEMBL8421568 | 0.81 | HPGD (0.62) | HPGDHDAC6HDAC4HDAC1ALDH1A1 | |
| SCHEMBL8418264 | 0.80 | HPGD (0.57) | HPGDALDH1A1LMNAPRNPRECQL | |
| SCHEMBL8419837 | 0.80 | HPGD (0.54) | HPGDHDAC6HDAC4HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8981084-B2 | Oxadiazole HDAC inhibitors | TEMPERO PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| US-20120322827-A1 | COMPOUNDS AND METHODS | TEMPERO PHARAMCEUTICALS. INC. | 2012-12-20 | — | — | US | disclosed |
| EP-2523560-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523664-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| US-20120289495-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals Inc. | 2012-11-15 | — | — | US | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088187-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088192-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322827-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | HPGD 2186/4885HDAC6 1991/4885HDAC4 2086/4885 |
| US-20120289495-A1 | COMPOUNDS AND METHODS | XDH, CCNY, TOP2B | HPGD 2446/4885HDAC6 1763/4885HDAC4 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.